“…One example concerns the analgesic glafenine, an anthranilic acid derivative which was registered more than 20 years ago in several European, Asian, South-American and African countries. Since 1972 several cases of anaphylaxis have been reported in the literature (Barral & Faivre, 1975;Cheymol et al, 1985;Davido et al, 1989;Faveret et al, 1975;Fischbein et al, 1984;Gaultier et al, 1972;Grand & Despret, 1973;Journe et al, 1980;Lainee et al, 1985;Maesen et al, 1976;Meyboom, 1976;Michaud & Doublet, 1976;Sauder et al, 1982; Sentilhes, 1978;Stricker et al, 1991;Weber et al, 1982) and several hundreds of cases have been reported to The Netherlands Centre for Monitoring of Adverse Reactions to Drugs. Since a high frequency of reporting does not prove that a particular adverse reaction has a high incidence, other methods than voluntary reporting had to be used to investigate further the hypothesis that anaphylaxis occurs more frequently in response to glafenine than to other analgesics.…”